Biote Corp. (BTMD)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
$1.04-15.45%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
QuarterlyIQ Insights · BTMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”
Stated in 3 of 3 supplied quarters. Management reported: ““Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”” ““Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterson, Biote’s interim Chief Executive Officer.” Revenue was $44.232 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.””
““Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedu…”
““During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable procedure revenue growth,” said Bret Christensen…”
As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.
Stated in 2 of 3 supplied quarters. Management reported: “As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.” “Key areas of focus include enhancing the practitioner experience; accelerating sales productivity; and driving growth across our network.”
“As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.”
“Key areas of focus include enhancing the practitioner experience; accelerating sales productivity; and driving growth across our network.”
• We continue to expect full-year 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate from 2025.
Stated in 2 of 3 supplied quarters. Management reported: “• We continue to expect full-year 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate from 2025.” “• 2026 Dietary supplements revenue is expected to grow at a mid to high single digit rate from 2025, unchanged from prior guidance.”
“• We continue to expect full-year 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate from 2025.”
“• 2026 Dietary supplements revenue is expected to grow at a mid to high single digit rate from 2025, unchanged from prior guidance.”
Summary and 2026 Financial Outlook Mr. Peterson concluded, “Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a b…
Stated in 2 of 3 supplied quarters. Management reported: “Summary and 2026 Financial Outlook Mr. Peterson concluded, “Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a basis for improvement.” “Summary and 2026 Financial Outlook Mr. Peterson concluded, “Our strategic initiatives program continues to guide the Company, and we are confident the foundational work completed over the past year has strengthened our business.”
“Summary and 2026 Financial Outlook Mr. Peterson concluded, “Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a b…”
“Summary and 2026 Financial Outlook Mr. Peterson concluded, “Our strategic initiatives program continues to guide the Company, and we are confident the foundational work completed over the past year h…”
Maintain disciplined execution to achieve Adjusted EBITDA above $25 million for full year 2026 despite first half challenges.
Over the trailing year it converted 1.14x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.